Published in J Hematol Oncol on June 03, 2016
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. J Hematol Oncol (2017) 0.77
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol (2017) 0.75
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. Onco Targets Ther (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med (2016) 2.54
Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol (2005) 2.33
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer (2002) 1.60
Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer (2008) 1.49
High frequency of genomic instability in Ewing family of tumors. Cancer Genet Cytogenet (2004) 1.49
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.44
Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol (2003) 1.42
Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene (2007) 1.13
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J Clin Oncol (2015) 1.13
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma (2013) 0.98
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? J Hematol Oncol (2015) 0.90
Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. J Hematol Oncol (2016) 0.82